Sinusitis treatment drugs market valued at about USD 2.1 billion in 2019 and expected to reach about USD 2.9 billion by 2029 with an estimated CAGR of 3% during the forecast period of 2021 to 2029.
Immunization of livestock has been carried out worldwide for centuries and is also accepted as a cost effective measure of controlling infections. Until recently, vaccines were either live attenuated or inactivated organisms formulated with oil-based adjuvant; however these methods and formulations were not very effective.
The global point of purchase displays market expected to expand at a CAGR of 5.9% during the forecast period from 2018 to 2026. The projected growth will be majorly driven by the continual efforts taken by brand owners to aggressively promote and market their newly launched or seasonal products at retail outlets.
The global active pharmaceutical ingredient market is growing significantly, valuing at US$ 152.6 Bn in 2017 and expected to reach US$ 273.7 Bn by 2026. Worldwide growing chronic diseases along with rising incidences for respiratory, cardiovascular, and oncology drives the overall market growth during the forecast period. In addition, new technological progresses in biologics & other specialty drugs along with favorable public and private funding in the pharmaceutical sector across various developing countries will further assist in the API market growth.
Odor control systems market value expected to hit US$ 4,070.5 Mn by 2026, expanding with a CAGR of 3.6% during the forecast period from 2018 to 2026. Principally governed by Asia Pacific, odor control systems market majorly driven by rising regulations for environmental protection by several governing bodies.
Bio-based polyethylene terephthalate (PET) market projected to exhibit the CAGR of 20.8% during the forecast period from 2018 to 2026. Bio-based polyethylene terephthalate (PET) market is currently gaining traction owing to rising demand for eco-friendly sustainable solution from end-use industries coupled with growing public awareness and increasing customer interest in bio-based plastics.
The global pulmonary arterial hypertension (PAH) treatment market accounted for a value of US$ 10,174.9 Mn in 2021 and expected to attain US$ 19,093.2 Mn by 2033. Drivers accountable for the market growth are worldwide growing elderly population along with increasing prevalence of pulmonary arterial hypertension due to rising risk factors such as connective tissue disorders, human immunodeficiency virus (HIV) infection, chronic liver diseases, lung diseases, sedentary lifestyle, and other idiopathic conditions.
Human race is facing a monstrous issue of water scarcity and water treatment plant is one of the few ways out of this calamity humans have brought onto themselves. Setting up water treatment plants allow some amount of wastewater to be used again for essential and lifesaving application.
In the U.S. the prevalence of pressure ulcers in intensive care units ranges from 16.6% to 20.7%. It is also reported that annually US$ 11 billion is spent on the treatment of pressure ulcers, with US$ 500 to US$ 70,000 spent on a single wound. In spite of availability of better assessment tools, new CMS ruling eliminating hospital reimbursement when stage 3 or 4 pressure ulcer is hospital acquired and emergence of new technologies to reduce pressure ulcers, the condition remains a significant healthcare problem.
RFID tags market worldwide is set to register robust CAGR through the forecast period from 2025 to 2033, rising from US$ 5,955.8 Mn in 2020. RFID tags are electronic devices embedded with an antenna attached to the goods/animals/personnel to be tracked. The demand for RFID tags is primarily governed by the continually growing penetration of RFID tracking systems worldwide.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.